Biomarker-guided therapy for colorectal cancer: strength in complexity
A Sveen, S Kopetz, RA Lothe - Nature Reviews Clinical Oncology, 2020 - nature.com
The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …
Smoking and colorectal cancer risk, overall and by molecular subtypes: a meta-analysis
METHODS: We conducted a systematic review and meta-analysis of epidemiological
studies on the association between cigarette smoking and CRC risk published up to …
studies on the association between cigarette smoking and CRC risk published up to …
[HTML][HTML] Exploring and modelling colon cancer inter-tumour heterogeneity: opportunities and challenges
Colon cancer inter-tumour heterogeneity is installed on multiple levels, ranging from (epi)
genetic driver events to signalling pathway rewiring reflected by differential gene expression …
genetic driver events to signalling pathway rewiring reflected by differential gene expression …
[HTML][HTML] The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer
GN Fanelli, CA Dal Pozzo, I Depetris, M Schirripa… - Cancer Cell …, 2020 - Springer
Colorectal cancer (CRC) is a complex and molecularly heterogeneous disease representing
one of the most frequent causes of cancer-related death worldwide. About 8–15% of CRCs …
one of the most frequent causes of cancer-related death worldwide. About 8–15% of CRCs …
[HTML][HTML] BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation
I Nakayama, T Hirota, E Shinozaki - Cancers, 2020 - mdpi.com
Simple Summary Colorectal cancer with a mutation in an oncogene BRAF has paid much
attention, as it comprises a population with dismal prognosis since two decades ago. A …
attention, as it comprises a population with dismal prognosis since two decades ago. A …
Kras codon 12 mutation is associated with more aggressive invasiveness in synchronous metastatic colorectal cancer (Mcrc): Retrospective research
K He, Y Wang, Y Zhong, X Pan, L Si… - OncoTargets and …, 2020 - Taylor & Francis
Objective To investigate the connection between mutant KRAS/NRAS/BRAF and
clinicopathological characteristics in therapy-naïve synchronous metastatic colorectal …
clinicopathological characteristics in therapy-naïve synchronous metastatic colorectal …
[HTML][HTML] What could microRNA expression tell us more about colorectal serrated pathway carcinogenesis?
M Peruhova, M Peshevska-Sekulovska… - World Journal of …, 2020 - ncbi.nlm.nih.gov
In the last two decades, the vision of a unique carcinogenesis model for colorectal
carcinoma (CRC) has completely changed. In addition to the adenoma to carcinoma …
carcinoma (CRC) has completely changed. In addition to the adenoma to carcinoma …
Substantial and sustained improvement of serrated polyp detection after a simple educational intervention: results from a prospective controlled trial
AGC Bleijenberg, ME van Leerdam, M Bargeman… - Gut, 2020 - gut.bmj.com
Objective Serrated polyps (SPs) are an important cause of postcolonoscopy colorectal
cancers (PCCRCs), which is likely the result of suboptimal SP detection during colonoscopy …
cancers (PCCRCs), which is likely the result of suboptimal SP detection during colonoscopy …
Receptor tyrosine kinase fusions act as a significant alternative driver of the serrated pathway in colorectal cancer development
Serrated polyps are a clinically and molecularly heterogeneous group of lesions that can
contribute to the development of colorectal cancers (CRCs). However, the molecular …
contribute to the development of colorectal cancers (CRCs). However, the molecular …